{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:08:06Z","timestamp":1783570086094,"version":"3.55.0"},"reference-count":36,"publisher":"American Diabetes Association","issue":"9","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,9,1]]},"abstract":"<jats:p>Lipid accumulation in nonadipose tissues is closely related to the development of type 2 diabetes in obese subjects. We examined the potential preventive effect of peroxisome proliferator-activated receptor (PPAR)-\u03b1 and PPAR-\u03b3 stimulation on the development of diabetes in obese diabetes-prone OLETF rats. Chronic administration of a PPAR-\u03b1 agonist (0.5% [wt\/wt] fenofibrate) or a PPAR-\u03b3 agonist (3 mg \u00b7 kg\u22121 \u00b7 day\u22121 rosiglitazone) completely prevented the development of glycosuria. Pancreatic islets from untreated OLETF rats underwent sequential hypertrophy and atrophy, which was completely prevented by chronic fenofibrate treatment. In contrast, rosiglitazone treatment did not affect islet hypertrophy at earlier stages but prevented \u03b2-cell atrophy at later stages. Fenofibrate treatment decreased body weight and visceral fat, whereas rosiglitazone treatment increased body weight. Despite the opposite effects on adiposity, both drugs were equally effective in improving insulin actions in skeletal muscle. Furthermore, both drugs significantly decreased the triglyceride content in the soleus muscle and pancreatic islets. The present study demonstrates that the PPAR-\u03b1 agonist fenofibrate prevents the development of diabetes in OLETF rats by reducing adiposity, improving peripheral insulin action, and exerting beneficial effects on pancreatic \u03b2-cells.<\/jats:p>","DOI":"10.2337\/diabetes.52.9.2331","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T19:04:22Z","timestamp":1173207862000},"page":"2331-2337","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":129,"title":["Peroxisome Proliferator-Activated Receptor (PPAR)-\u03b1 Activation Prevents Diabetes in OLETF Rats"],"prefix":"10.2337","volume":"52","author":[{"given":"Eun Hee","family":"Koh","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Seon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joong-Yeol","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Sik","family":"Kim","sequence":"additional","affiliation":[{"name":"Asan Institute for Life Sciences, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Young","family":"Youn","sequence":"additional","affiliation":[{"name":"Asan Institute for Life Sciences, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Sun","family":"Park","sequence":"additional","affiliation":[{"name":"Asan Institute for Life Sciences, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Hyun","family":"Youn","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, University of Southern California Keck School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Up","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031207324350600_R1","doi-asserted-by":"crossref","unstructured":"Kelley DE, Goodpaster BH: Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance. Diabetes Care\u200824:933\u2013941,2001","DOI":"10.2337\/diacare.24.5.933"},{"key":"2022031207324350600_R2","doi-asserted-by":"crossref","unstructured":"Unger RH, Zhou YT: Lipotoxicity of \u03b2-cells in obesity and in other causes of fatty acid spillover. Diabetes\u200850:S118\u2013S121,2001","DOI":"10.2337\/diabetes.50.2007.S118"},{"key":"2022031207324350600_R3","doi-asserted-by":"crossref","unstructured":"Lowell BB: PPAR \u03b3: an essential regulator of adipogenesis and modulator of fat cell function. Cell\u200899:239\u2013242,1999","DOI":"10.1016\/S0092-8674(00)81654-2"},{"key":"2022031207324350600_R4","doi-asserted-by":"crossref","unstructured":"Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). J Biol Chem\u2008270:12953\u201312956,1995","DOI":"10.1074\/jbc.270.22.12953"},{"key":"2022031207324350600_R5","doi-asserted-by":"crossref","unstructured":"Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW: Peroxisome proliferator-activated receptor (PPAR)-\u03b1 activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-\u03b3 activation. Diabetes\u200850:411\u2013417,2001","DOI":"10.2337\/diabetes.50.2.411"},{"key":"2022031207324350600_R6","doi-asserted-by":"crossref","unstructured":"Shimabukuro M, Zhou YT, Lee Y, Unger RH: Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem\u2008273:3547\u20133550,1998","DOI":"10.1074\/jbc.273.6.3547"},{"key":"2022031207324350600_R7","doi-asserted-by":"crossref","unstructured":"Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-\u03b1 in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes\u200846:1319\u20131327,1997","DOI":"10.2337\/diab.46.8.1319"},{"key":"2022031207324350600_R8","doi-asserted-by":"crossref","unstructured":"Furnsinn C, Waldhausl W: Thiazolidinediones: metabolic actions in vitro. Diabetologia\u200845:1211\u20131223,2002","DOI":"10.1007\/s00125-002-0899-1"},{"key":"2022031207324350600_R9","doi-asserted-by":"crossref","unstructured":"Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes\u200851:2698\u20132674,2002","DOI":"10.2337\/diabetes.51.10.2968"},{"key":"2022031207324350600_R10","doi-asserted-by":"crossref","unstructured":"Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Retiman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med\u20087:941\u2013946,2001","DOI":"10.1038\/90984"},{"key":"2022031207324350600_R11","doi-asserted-by":"crossref","unstructured":"Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology\u2008137:354\u2013366,1996","DOI":"10.1210\/endo.137.1.8536636"},{"key":"2022031207324350600_R12","doi-asserted-by":"crossref","unstructured":"Gulick T, Cresci S, Caira T, Moore DD, Kelly DP: The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A\u200891:11012\u201311016,1994","DOI":"10.1073\/pnas.91.23.11012"},{"key":"2022031207324350600_R13","doi-asserted-by":"crossref","unstructured":"Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, Dohm GL: Peroxisome proliferator-activated receptor \u03b1 regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes\u200851:901\u2013909,2002","DOI":"10.2337\/diabetes.51.4.901"},{"key":"2022031207324350600_R14","doi-asserted-by":"crossref","unstructured":"Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem\u2008275:16638\u201316642,2000","DOI":"10.1074\/jbc.275.22.16638"},{"key":"2022031207324350600_R15","doi-asserted-by":"crossref","unstructured":"Zhou YT, ShimabukuroM, Wang MY, Lee Y, Higa M, Milburn JL, Newgard CB, Unger RH: Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci U S A\u200895:8898\u20138903,1998","DOI":"10.1073\/pnas.95.15.8898"},{"key":"2022031207324350600_R16","doi-asserted-by":"crossref","unstructured":"Suzuki K, Bonner-Weir S, Hollister J, Weir GC: A method for estimating number and mass of islets transplanted within a membrane device. Cell Transplant\u20085:613\u2013625,1996","DOI":"10.1177\/096368979600500604"},{"key":"2022031207324350600_R17","doi-asserted-by":"crossref","unstructured":"Ross R, Leger L, Guardo R, De Guise J, Pike BG: Adipose tissue volume measured by magnetic resonance imaging and computerized tomography in rats. J Appl Physiol\u200870:2164\u20132172,1991","DOI":"10.1152\/jappl.1991.70.5.2164"},{"key":"2022031207324350600_R18","doi-asserted-by":"crossref","unstructured":"Kim CH, Youn JH, Park JY, Hong SK, Park KS, Park SW, Suh KI, Lee KU: Effects of high-fat diet and exercise training on intracellular glucose metabolism in rats. Am J Physiol\u2008278:E977\u2013E984,2000","DOI":"10.1152\/ajpendo.2000.278.6.E977"},{"key":"2022031207324350600_R19","doi-asserted-by":"crossref","unstructured":"Youn JH, Kim JK, Buchanan TA: Time courses of changes in hepatic and skeletal muscle insulin action and GLUT4 protein in skeletal muscle after STZ injection. Diabetes\u200843:564\u2013571,1994","DOI":"10.2337\/diabetes.43.4.564"},{"key":"2022031207324350600_R20","doi-asserted-by":"crossref","unstructured":"Kraegen EW, James DE, Jenkins AB, Chisholm DJ: Dose response curve for in vitro insulin sensitivity in individual tissues in rats. Am J Physiol\u2008248:E353\u2013E362,1985","DOI":"10.1152\/ajpendo.1985.248.3.E353"},{"key":"2022031207324350600_R21","doi-asserted-by":"crossref","unstructured":"Chan TM, Exton JH: A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem\u200871:96\u2013105,1976","DOI":"10.1016\/0003-2697(76)90014-2"},{"key":"2022031207324350600_R22","doi-asserted-by":"crossref","unstructured":"Lee Y, Hirose H, Zhou YT, Esser V, McGarry JD, Unger RH: Increased lipogenic capacity of the islets of obese rats. Diabetes\u200846:408\u2013413,1997","DOI":"10.2337\/diabetes.46.3.408"},{"key":"2022031207324350600_R23","doi-asserted-by":"crossref","unstructured":"Gotoh M, Maki T, Satomi S, Porter J, Bonner-Weir S, O\u2019Hara CJ, Monaco AP: Reproducible high yield of rat islets by stationary in vitro digestion following pancreatic ductal or portal venous collagenase injection. Transplantation\u200843:725\u2013730,1987","DOI":"10.1097\/00007890-198705000-00024"},{"key":"2022031207324350600_R24","doi-asserted-by":"crossref","unstructured":"Briaud I, Harmon JS, Kelpe CL, Segu VB, Poitout V: Lipotoxicity of the pancreatic beta-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes\u200850:315\u2013321,2001","DOI":"10.2337\/diabetes.50.2.315"},{"key":"2022031207324350600_R25","doi-asserted-by":"crossref","unstructured":"Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW: The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism\u200846:935\u2013942,1997","DOI":"10.1016\/S0026-0495(97)90083-4"},{"key":"2022031207324350600_R26","doi-asserted-by":"crossref","unstructured":"Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW: Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study: the Troglitazone Study Group. J Clin Endocrinol Metab\u200883:3169\u20133176,1998","DOI":"10.1210\/jc.83.9.3169"},{"key":"2022031207324350600_R27","doi-asserted-by":"crossref","unstructured":"Oakes ND, Thalen PG, Jacinto SM, Ljung B: Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes\u200850:1158\u20131165,2001","DOI":"10.2337\/diabetes.50.5.1158"},{"key":"2022031207324350600_R28","doi-asserted-by":"crossref","unstructured":"Cha BS, Ciaraldi TP, Carter L: Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia\u200844:444\u2013452,2001","DOI":"10.1007\/s001250051642"},{"key":"2022031207324350600_R29","doi-asserted-by":"crossref","unstructured":"Piro S, Anello M, Di Pietro C, Lizzio MN, Patane G, Rabuazzo AM, Vigneri R, Purrello M, Purrello F: Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism\u200851:1340\u20131347,2002","DOI":"10.1053\/meta.2002.35200"},{"key":"2022031207324350600_R30","doi-asserted-by":"crossref","unstructured":"Steil GM, Trivedi N, Jonas JC, Hasenkamp WM, Sharma A, Bonner-Weir S, Weir GC: Adaptation of beta cell mass to substrate oversupply: enhanced function with normal gene expression. Am J Physiol\u2008280:E788\u2013E796,2001","DOI":"10.1152\/ajpendo.2001.280.5.E788"},{"key":"2022031207324350600_R31","doi-asserted-by":"crossref","unstructured":"Man ZW, Zhu M, Noma Y, Toide K, Sato T, Asahi Y, Hirashima T, Mori S, Kawano K, Mizuno A, Sano T, Shima K: Impaired \u03b2-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia in OLETF rat, a model of spontaneous NIDDM. Diabetes\u200846:1718\u20131724,1997","DOI":"10.2337\/diabetes.46.11.1718"},{"key":"2022031207324350600_R32","doi-asserted-by":"crossref","unstructured":"Knopp RH: Drug treatment of lipid disorders. N Engl J Med\u2008341:498\u2013511,1999","DOI":"10.1056\/NEJM199908123410707"},{"key":"2022031207324350600_R33","doi-asserted-by":"crossref","unstructured":"Lawrence JW, Li Y, Chen S, DeLuca JG: Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha: PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem\u2008276:31521\u201331527,2001","DOI":"10.1074\/jbc.M103306200"},{"key":"2022031207324350600_R34","doi-asserted-by":"crossref","unstructured":"Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B, Tugwood J, Wahli W: Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?Regul Toxicol Pharmacol\u200827:47\u201360,1998","DOI":"10.1006\/rtph.1997.1163"},{"key":"2022031207324350600_R35","doi-asserted-by":"crossref","unstructured":"Sane T, Knudsen P, Vuorinen-Markkola H, Yki-Jarvinen H, Taskinen MR: Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism\u200844:589\u2013596,1995","DOI":"10.1016\/0026-0495(95)90115-9"},{"key":"2022031207324350600_R36","doi-asserted-by":"crossref","unstructured":"Asplund-Carlson A: Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia. J Cardiovasc Risk\u20083:385\u2013390,1996","DOI":"10.1097\/00043798-199608000-00009"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/52\/9\/2331\/650215\/db0903002331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/52\/9\/2331\/650215\/db0903002331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:19:06Z","timestamp":1667405946000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/52\/9\/2331\/11522\/Peroxisome-Proliferator-Activated-Receptor-PPAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,1]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diabetes.52.9.2331","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,1]]}}}